Analyst Starts Coverage on United Therapeutics with Optimism; Check Out the Top 5 Initiations for Friday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 26 2025
0mins
Source: Benzinga
Analyst Coverage Initiations: Several Wall Street analysts have initiated coverage on various companies, including First Horizon Corporation, Valmont Industries, Lyell Immunopharma, Spyre Therapeutics, and United Therapeutics, with ratings ranging from Neutral to Buy and price targets set above current share prices.
Price Targets and Current Share Prices: The price targets announced by analysts include $24 for First Horizon, $480 for Valmont Industries, $20 for Lyell Immunopharma, $43 for Spyre Therapeutics, and $569 for United Therapeutics, with current share prices being $22.66, $364.66, $12.72, $15.61, and $425.42 respectively.
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 534.50 USD with a low forecast of 423.00 USD and a high forecast of 645.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 472.060
Low
423.00
Averages
534.50
High
645.00
Current: 472.060
Low
423.00
Averages
534.50
High
645.00
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
